Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31645488 | 0.84 | S1PR3 (0.39) | NAAAGBA1EPHX1CA2ACHE | |
| SCHEMBL31645615 | 0.84 | S1PR3 (0.39) | NAAAGBA1EPHX1CA2ACHE | |
| SCHEMBL31645650 | 0.84 | S1PR3 (0.39) | NAAAGBA1EPHX1CA2ACHE | |
| SCHEMBL31645257 | 0.84 | S1PR3 (0.39) | NAAAGBA1EPHX1CA2ACHE | |
| SCHEMBL31409863 | 0.81 | GBA1 (0.54) | NAAAGBA1EPHX1CA2ACHE | |
| SCHEMBL296648 | 0.80 | NAAA (0.55) | NAAAEPHX1CA2ACHETSHR | |
| SCHEMBL5179238 | 0.80 | NAAA (0.55) | NAAAEPHX1CA2ACHETSHR | |
| SCHEMBL730516 | 0.80 | NAAA (0.55) | NAAAEPHX1CA2ACHETSHR | |
| SCHEMBL698630 | 0.80 | NAAA (0.55) | NAAAEPHX1CA2ACHETSHR | |
| SCHEMBL20512287 | 0.80 | NAAA (0.55) | NAAAEPHX1CA2ACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4402123-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773061-B2 | Cyclic lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | NAAA 1398/4885GBA1 236/4885EPHX1 2960/4885 |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | NAAA 1398/4885GBA1 236/4885EPHX1 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.